Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Antonarakis on Galeterone for Prostate Cancer

Emmanuel S. Antonarakis, MBBCh
Published: Thursday, Dec 17, 2015



Emmanuel Antonarakis, MBBCh, associate professor of Oncology, associate professor of Urology at Johns Hopkins Medicine, discusses the use of galeterone in prostate cancer.

Galeterone is an oral androgen receptor inhibitor which also inhibits the ip17 enzyme, similarly to abiraterone.

It can also degrade the androgen receptor protein and ARV7. Because of this, galeterone may demonstrate some activity in patients who have tumors that express ARV7.

The ARMOR III trial is investigating galeterone versus enzalutamide for ARV7-positive patients.
 


Emmanuel Antonarakis, MBBCh, associate professor of Oncology, associate professor of Urology at Johns Hopkins Medicine, discusses the use of galeterone in prostate cancer.

Galeterone is an oral androgen receptor inhibitor which also inhibits the ip17 enzyme, similarly to abiraterone.

It can also degrade the androgen receptor protein and ARV7. Because of this, galeterone may demonstrate some activity in patients who have tumors that express ARV7.

The ARMOR III trial is investigating galeterone versus enzalutamide for ARV7-positive patients.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x